Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31484533.
- Also identified by DOI 10.1186/s13018-019-1301-z and PMC identifier 6727552.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Osteosarcoma is aggressive and prognostic biomarkers are important to predict the outcomes of surgery and chemotherapy. Here, we investigated the potential of transferrin receptor-1 (TfR1) and vascular endothelial growth factor (VEGF) as prognostic markers of osteosarcoma. TfR1 and VEGF in osteosarcoma samples from a cohort of 53 osteosarcoma patients were detected by immunohistochemistry analysis. The correlation of TfR1 and VEGF levels with clinicopathological parameters was analyzed by Pearson chi-square and Spearman-rho tests. Overall patient survival was analyzed by the Kaplan-Meier method. We found that TfR1 and VEGF expression levels were low in 20.8% and 18.9%; modest in 35.8% and 35.8%; and high in 43.4% and 45.3% of osteosarcoma patients, respectively. TfR1 and VEGF expression was significantly correlated to histologic grade, Enneking stage, and distant metastasis. TfR1 expression was significantly correlated to VEGF expression and both TfR1 expression and VEGF expression were correlated to shorter overall survival. TfR1 and VEGF are potential prognostic factors for osteosarcoma.
Medical subject headings
- Antigens, CD
- Biomarkers, Tumor
- Bone Neoplasms
- Osteosarcoma
- Receptors, Transferrin
- Vascular Endothelial Growth Factor A